Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage
Open Access
- 1 March 2012
- journal article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 7, 1613-1621
- https://doi.org/10.2147/IJN.S30104
Abstract
The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes is a promising new approach for the visualization of enzymes. The cell-penetrating function of a polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic interactions with a polyanionic peptide. Proteolysis of a proteinase-sensitive substrate present between the CPP and polyanionic peptide affords dissociation of both domains and enables the activated CPP to enter cells. This ACPP strategy could also be used to modify antitumor agents for tumor-targeting therapy. Here, we aimed to develop a conjugate of ACPP with antitumor drug doxorubicin (DOX) sensitive to matrix metalloproteinase-2 and -9 (MMP-2/9) for tumor-targeting therapy purposes. The ACPP-DOX conjugate was successfully synthesized. Enzymatic cleavage of ACPP-DOX conjugate by matrix metalloproteinase (MMP)-2/9 indicated that the activation of ACPP-DOX occurred in an enzyme concentration–dependent manner. Flow cytometry and laser confocal microscope studies revealed that the cellular uptake of ACPP-DOX was enhanced after enzymatic-triggered activation and was higher in HT-1080 cells (overexpressed MMPs) than in MCF-7 cells (under-expressed MMPs). The antiproliferative assay showed that ACPP had little toxicity and that ACPP-DOX effectively inhibited HT-1080 cell proliferation. These experiments revealed that the ACPP-DOX conjugate could be triggered by MMP-2/9, which enabled the activated CPP-DOX to enter cells. ACPP-DOX conjugate may be a potential prodrug delivery system used to carry antitumor drugs for MMP-related tumor therapy.Keywords
This publication has 38 references indexed in Scilit:
- Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231Cancer Letters, 2009
- Recent advances in the use of cell-penetrating peptides for medical and biological applications☆Advanced Drug Delivery Reviews, 2009
- Proteolysis: A Biological Process Adapted in Drug Delivery, Therapy, and ImagingBioconjugate Chemistry, 2009
- Cell-penetrating and cell-targeting peptides in drug deliveryBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2008
- Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transportersProceedings of the National Academy of Sciences, 2008
- Progress in matrix metalloproteinase researchMolecular Aspects of Medicine, 2008
- Proximity-activated nanoparticles: in vitro performance of specific structural modification by enzymatic cleavageInternational Journal of Nanomedicine, 2008
- Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free mediumLife Sciences, 2007
- Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptideBiochemical Pharmacology, 2006
- Synthesis of doxorubicin–peptide conjugate with multidrug resistant tumor cell killing activityBioorganic & Medicinal Chemistry Letters, 2005